Ricevi le ultime notizie sulle azioni TransCode Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di RNAZ

Ultime notizie per

TRANSCODE THERAPEUTICS INC

TransCode Therapeutics

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

New,York,Ny - usa-may,5,,2015,Packages,Of,Tyson,Brand,Chicken

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

HSIC

RNAZ

Wall Street guarda ai report trimestrali di importanti aziende come Tyson Foods e Cummins. Scopri i dettagli.

Tyson Foods, Ford e altre 3 azioni da tenere d&#39;occhio in questo lunedì

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics Inc

Offerings

Press Releases

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

Stock Split

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

LXRX

PRSO

PRTG

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Alzamend Neuro

Aprea Therapeutics

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

enGene Holdings

ESSA Pharma

Ernexa Therapeutics

Evogene

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Genprex

HCW Biologics

IN8bio

Kala Bio

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

SILO Pharma

Soligenix

VivoSim Labs

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

TransCode Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO